Trigemina, Inc. Company Presentation
Trigemina was founded by Stanford and other scientists in order to make use of the naso-cerebral pathway for administration of analgesic peptides to the trigeminal system and other brain sites. Our formulation of nasal oxytocin alleviates pain in rodent models and human tonic and chronic head pain conditions, including chronic migraine. Our goal is to partner with a pharmaceutical company that has the resources to fully develop the drug as well as its marketing, manufacture, and sales.
Session ID: 2192